PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway.

Saved in:

Bibliographic Details
Title:	PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway.
Authors:	Ma M; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China., Liu F; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China., Yin X; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China., Yue J; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China., Duan Y; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China., Tang J; Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.
Source:	General physiology and biophysics [Gen Physiol Biophys] 2026 Mar; Vol. 45 (2), pp. 153-165.
Publication Type:	Journal Article
Journal Info:	Publisher: Ústav molekulárnej fyziológie a genetiky SAV Country of Publication: Slovakia NLM ID: 8400604 Publication Model: Print Cited Medium: Print ISSN: 0231-5882 (Print) Linking ISSN: 02315882 NLM ISO Abbreviation: Gen Physiol Biophys Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	0231-5882
DOI:	10.4149/gpb_2025043